TDAC Clears Extension Vote with 95% Approval, 85% of Shares Retained Ahead of Prologium Merger
Translational Development Acquisition Company (NYSE: TDAC) announced June 17, 2026 shareholder vote results showing 95% approval for extending the SPAC's life and 85% of shares not redeemed, preserving $156.8mm in trust for its pending merger with battery maker Prologium.
Translational Development Acquisition Company (NYSE: ) announced shareholder vote results from its June 17, 2026 meeting in which 95% of shares voted approved extending the SPAC's life and 85% of shares were not redeemed, preserving $156.8mm in the trust account.
The extension vote allows to maintain its capital structure as it moves toward completing the merger with Prologium announced May 27, 2026. Holders of Class A common stock were offered the opportunity to redeem their shares for a pro-rata portion of the trust account in connection with the meeting. The 15% redemption rate left the vehicle with substantially more working capital than many SPAC extensions during this cycle.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.